Statistical analysis plan (SAP)

***The effects of different doses of exercise on pancreatic β-cell function in patients with newly diagnosed type 2 diabetes***

Version: 1.0

Version date: Nov. 12th 2021

Trial registration: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Trial registration number: NCT03769883

Ethical committee: Capital Region of Denmark

Approval number: H-18038298

SAP authors: Mathias Ried-Larsen, Grit E. Legaard, Mark P. P. Lyngbæk

Sponsor - Investigator: Mathias Ried-Larsen, Senior Researcher, Centre for Physical Activity Research, Dept. 7641, Rigshospitalet, Denmark

Investigators: Grit Elster Legaard, MD and Mark Preben Printz Lyngbæk, MD, Centre for Physical Activity Research, Dept. 7641, Rigshospitalet, Denmark

Statistical advisor: Robin Christensen, MSc, PhD; Professor of Biostatistics and Clinical Epidemiology; Head of Musculoskeletal Statistics Unit.

Table of Contents

[BACKGROUND AND RATIONAL 3](#_Toc87442267)

[OBJECTIVES 4](#_Toc87442268)

[HYPOTHESIS 5](#_Toc87442269)

[TRIAL DESIGN, DATA COLLECTION AND OUTCOMES ASSESSMENT 6](#_Toc87442270)

[OUTCOMES 6](#_Toc87442271)

[STUDY POPULATION, ANALYSIS SET AND STATISTICAL PRINCIPLES 9](#_Toc87442272)

[STATISTICAL METHODS 11](#_Toc87442273)

[DEVIATIONS FROM THE ORIGINAL PROTOCOL 12](#_Toc87442274)

[IMPLEMENTATION OF THE SAP 14](#_Toc87442275)

[EXPECTED WRITING COMMITTEE 14](#_Toc87442276)

[EXPECTED OUTLINE OF THE REPORT 15](#_Toc87442277)

[OVERVIEW OF CONTENT (Unformatted tables with specific variables are placed at the end of the text) 15](#_Toc87442278)

[TABLES (In paper) 15](#_Toc87442279)

[FIGURES (In paper) 15](#_Toc87442280)

[ONLINE ONLY (Tables) 16](#_Toc87442281)

[ONLINE ONLY (Figures) 17](#_Toc87442282)

[REFERENCES 19](#_Toc87442283)

[UNFORMATTED TABLES WITH INTENDED CONTENT 21](#_Toc87442284)

# BACKGROUND AND RATIONAL

The etiology, pathophysiology and treatment of type 2 diabetes (T2D) are undeniably multifactorial and the understanding of T2D is increasing rapidly, but reducing obesity remains essential to improve β-cell function. However, a residue β-cell capacity appears to be essential for remission emphasizing the need for lifestyle intervention early in the clinical management [1].

While exercise is less recognized as an efficient therapy for weight loss, dietary therapy is [2]. With the recent advantages in the role of very low-calorie diets on β-cell function [1, 3], it is important to study the role of exercise therapy in combination with dietary-induced weight loss to fully understand the implications for patient care. However, only a few studies have focused on the effects of exercise on pancreatic β-cell function in T2D and discrepancies regarding the effect exist [4-8]. The discrepancies may relate to the assessment of β-cell function [9], failure to correct for the change in peripheral insulin sensitivity, concomitant pharmacological therapy and the pre-trial insulin secretory capacity. Moreover, exercise intensity, volume and modality may play an essential role in the reduction of HbA1c [10-14]. Thus, current evidence suggests that physical activity may *directly* improve β-cell mass and β-cell function[15], and may also *indirectly* improve β-cell function and mass by inducing β-cell rest via reductions in systemic inflammation and metabolic stress (i.e. gluco- and lipotoxicity). However, evidence is limited from human studies investigating the relationship of exercise volume, intensity, frequency, and dose-dependency on β-cell function[15]. As a consequence, knowledge about the exercise training dose needed to reduce micro- and macrovascular complications in T2D is almost non-existing [12, 16-23]. As most clinical exercise interventions in T2D base their conclusions on HbA1c, the significance of exercise training in the clinical care of prevalent T2D is challenged [11, 23-25] and investigating β-cell function with different volumes of exercise in addition to a diet-induced weight loss is of clinical relevance. A full description of the rationale behind the study has been published elsewhere[26]. We propose that combining a moderate diet-induced weight loss with exercise training may dose-dependently improve pancreatic β-cell function.

# OBJECTIVES

*Primary aim:* To investigate the effect of exercise training volume on pancreatic β-cell function after 16 weeks in patients with short standing T2D.

*Secondary aims:* To investigate the effect of exercise training volume on mechanisms underlying β–cell function.

*Primary objective:* To compare the effect of high (HED) *or* moderate (MED) volumes of exercise in combination with a dietary intervention, relative to the control (CON) *or* diet (DCON) comparator, on changes in the late-phase disposition index (DI) during the final 30 minutes of hyperglycemic phase of the hyperglycemic clamp from baseline to week 16, in patients with short standing T2D.

*Major secondary objective:* To compare the effect of high (HED) *or* moderate (MED) volumes of exercise in combination with a dietary intervention, relative to the control (CON) *or* diet (DCON) comparator, on changes in insulin secretion rate and insulin sensitivity derived from hyperglycemic clamp AND oral insulinogenic and insulin sensitivity index derived from the mixed meal tolerance test (MMTT) from baseline to week 16, in patients with short standing T2D.

*Other objectives:* To compare the effect of high (HED) *or* moderate (MED) volumes of exercise in combination with a dietary intervention, relative to the control (CON) *or* diet (DCON) comparator on changes in glucose disposal, postprandial glycemic control, GLP-1 and arginine stimulated insulin secretion, fasting blood glucose control, fasting blood lipids, blood pressure, physical function from baseline to week 16, in patients with short standing T2D.

# HYPOTHESIS

*Primary:*The effect of exercise training on pancreatic β-cell function (assessed as late-phase disposition index) increases with increasing volumes of exercise in combination with a diet intervention across a 16-week intervention in patients with T2D of short duration. Specifically, it is expected that both moderate volume and high volumes of exercise in combination with a dietary intervention are superior to the control intervention in improving pancreatic β-cell function.

The hierarchy of the hypotheses and subsequent claims for the primary outcome are as follows;

1. High-volume exercise and diet group (HED) is superior to the control intervention (CON) in increasing the late phase disposition index from baseline (visit 1) to follow-up (visit 7). Superiority is claimed if the difference in change between the groups favours the HED group.
2. Medium-volume exercise and diet group (MED) is superior to the control intervention in increasing the late phase disposition index from baseline (visit 1) to follow-up (visit 7). Superiority is claimed if the difference in change between the groups favours the MED group.
3. The diet control group (DCON) is superior to the control intervention in increasing the late phase disposition index from baseline (visit 1) to follow-up (visit 7). Superiority is claimed if the difference in change between the groups favours the DCON group.
4. HED is superior to the DCON intervention in increasing the late phase disposition index from baseline (visit 1) to follow-up (visit 7). Superiority is claimed if the difference in change between the groups favours the HED group.
5. MED is superior to the DCON intervention in increasing the late phase disposition index from baseline (visit 1) to follow-up (visit 7). Superiority is claimed if the difference in change between the groups favours the MED group.
6. HED is superior to the MED intervention in increasing the late phase disposition index from baseline (visit 1) to follow-up (visit 7). Superiority is claimed if the difference in change between the groups favours the HED group.

# TRIAL DESIGN, DATA COLLECTION AND OUTCOMES ASSESSMENT

All procedure and detailed information about the trial design, eligibility and methods, including a detailed description of the interventions has been published elsewhere [26]. Briefly, the study is a parallel-group, 4-arm assessor-blinded, randomised, clinical trial with 16 weeks of intervention. Participants are randomly allocated (1:1:1:1, stratified by sex) to four groups; 1) No intervention, 2) Dietary intervention, 3) Dietary intervention + moderate volume exercise (3 sessions/week), 4) Dietary intervention + high volume exercise (6 sessions/week). The study is registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) ([NCT03769883](https://clinicaltrials.gov/show/NCT03769883)) and approved by the Scientific Ethical Committee of the Capital Region of Denmark (approval number H-18038298) prior to commencement of any study procedures. Primary place of study execution and data collection is the Centre for Physical Activity Research (CFAS), Rigshospitalet, section 7641, Tagensvej 20, DK-2200 Copenhagen (visiting address); Blegdamsvej 9, DK-2100 Copenhagen (postal address), Telephone: (+45) 3545 7641.

It is expected that an exercise intervention will increase late-phase disposition index derived from a hyperglycemic clamp by 1.5 (au.) more than the control group, with a standard deviation of 1.5 (au.) of the change in the exercise and 1.0 (au.) in the control group[4]. For a contrast in a one-way ANOVA with four means (1.5, 1.0, 0.5, 0.0) and contrast coefficients (1, 0, 0, -1) using a two-sided significance level of 0.05, assuming an error standard deviation of 1.5 and a balanced design, a total sample size of 80 participants corresponds to an approximate statistical power of 87.7%. Thus, at least 20 participants are recruited per group.

## OUTCOMES

The domains and measurements for this article as well the hierarchal structure of the hereof are based on the pre-specified designation located in the trial registration (published prior to recruitment initiation) and our published protocol published prior to last patient-last-visit (described in Table 5)[26].

**Primary outcome (change, timeframe 0 to 16 weeks)**

Domain: beta-cell function

Measurement: hyperglycemic clamp

* Late-phase disposition index during the last 30 minutes of the glucose infusion in the hyperglycemic clamp

**Major outcomes (change, timeframe 0 to 16 weeks)**

Domain: beta-cell function

Measurement: hyperglycemic clamp

* Late-phase insulin sensitivity index (mean Glucose infusion rate over last 30 min of the hyperglycemic clamp phase/ (mean insulin × glucose))
* Late-phase insulin secretion rate (mean deconvoluted C-peptide measurements over last 30 min of the hyperglycemic clamp phase/ mean glucose)

Domain: post-prandial glycemic control

Measurement: mixed meal tolerance test:

* Oral disposition index
* Oral insulin sensitivity index (Matsuda index)
* Oral insulin secretion index

**Other secondary outcomes (change, timeframe 0 to 16 weeks).**

Domain: β cell function

Measurement: hyperglycemic clamp

* GLP-1 stimulated insulin secretion rate and C-peptide
* Arginine stimulated insulin secretion rate and C-peptide
* First phase C-peptide and insulin secretion defined as the peak concentration during the initial 10 minutes of the hyperglycemic clamp
* Basal rate of glucose disappearance (Rd)
* Basal rate of endogenous glucose appearance (Ra)
* Rate of glucose disappearance (Rd) during steady-state hyperglycemia
* Rate of glucose endogenous appearance (Ra) during steady-state hyperglycemia

Domain: post-prandial glycemic control

Measurement: mixed meal tolerance test:

* iAUC of glucose, insulin, glucagon and C-peptide
* tAUC of glucose, insulin, glucagon and C-peptide
* Glucagon like peptide-1
* Gastric inhibitory peptide
* Gastric emptying

Domain: Body anthropometrics and composition

* Body weight
* Body mass index (BMI)

Domain: Clinical, functional markers of mechanism

Measurement: fasting blood samples (plasma)

* Glycated hemoglobin A1c
* Glucose
* C-peptide
* Insulin
* Triglyceride
* Low density lipoprotein

Domain: Blood pressure

Measurement: Home blood pressure monitoring

* Avg. home systolic blood pressure
* Avg. home diastolic blood pressure

Domain: Physical function

Measurements: VO2max test (indirect calorimetry and 1 repetition max in chest press and leg-extensions)

* Maximal oxygen consumption
* Maximal oxygen consumption relative to body weight
* Upper and lower body maximal strength

## STUDY POPULATION, ANALYSIS SET AND STATISTICAL PRINCIPLES

Inclusion and exclusion criteria have been published elsewhere [26].The primary analysis will be based on the family of the intention-to-treat population, defined as the *as-observed population* (missing data will not be imputed in the primary analysis) [27, 28], and the set of participants who are as close as possible to the intended intervention protocol, i.e. per-protocol (criteria described in the box 1) as a sensitivity analysis. The ‘Full Analysis Set’ for the intention-to-treat will thus be derived from the set of all randomized participants by minimal and justified elimination of participants. Therefore, all participants allocated to a treatment group (CON, DCON, MED or HED) will be followed up, assessed and analysed as members of that group irrespective of their compliance to the planned course of treatment.

P-values and 95% confidence intervals will be presented for the between-group difference in change comparisons and only 95% confidence intervals will be presented for the within-group (0-16 weeks) differences. Statistical significance will be claimed if the null hypothesis is rejected at the alpha level of 0.05 (two-sided). No corrections for multiplicity will be performed. To maintain the family-wise type 1 error rate on the primary outcome, a hierarchical analytic approach is engaged [29]; if we fail to progress from any of the subsequent steps (p > 0.05) we will interpret p-values and CI’s numerically as indicators of associations.

Between group comparisons for effect size estimation (difference in change from 0-16 weeks, based on a superiority assumption) will be completed for all outcomes in the following order:

1. CON vs. HED. If a difference is present (p < 0.05, 2-sided) then the next between group comparison is performed. If not – then sequence is terminated.
2. CON vs. MED. If a difference is present (p < 0.05, 2-sided) then the next between group comparison is performed. If not – then sequence is terminated.
3. CON vs. DCON. If a difference is present (p < 0.05, 2-sided) then the next between group comparison is performed. If not – then sequence is terminated.
4. DCON vs. HED. If a difference is present (p < 0.05, 2-sided) then the next between group comparison is performed. If not – then sequence is terminated.
5. DCON vs. MED. If a difference is present (p < 0.05, 2-sided) then the next between group comparison is performed. If not – then sequence is terminated.
6. MED vs. HED.

All non-hypothesis-based comparisons (i.e. on the secondary outcomes) are per definition considered exploratory and supportive to the interpretation of the primary outcome.

**BOX 1 Per-protocol definition (all criteria present)**

**Control group:**

* The primary outcome is assessed at both baseline and after 16 weeks follow-up (i.e. complete case).

**Diet control group:**

* The primary outcome is assessed at both baseline and after 16 weeks follow-up (i.e. complete case).
* Do not exceed +/- 30% of the prescribed energy intake as assessed by their dietary records (assessed as the mean energy intake across that latter 16 weeks, excluding 1-week vacation administered following week 2 of the intervention)

**Exercise and diet groups:**

* The primary outcome is assessed at both baseline and after 16 weeks follow-up (i.e. complete case).
* ≥ 70% of the prescribed exercise volume across the intervention period (excluding the initial two weeks of familization and potentially one week of vacation permitted after week two of the intervention). Exercise volume is calculated separately for aerobic and resistance training and ≥ 70% of the volume of each type should be achieved. For aerobic training ≥ 70% of prescribed training time (minutes) should be within the target heart rate zones. For resistance training, ≥ 70% of prescribed sets should be performed at or below the prescribed maximum RIR.
* Do not exceed +/- 30% of the prescribed energy intake as assessed by their dietary records (assessed as the mean energy intake across that latter 16 weeks, excluding 1-week vacation administered following week 2 of the intervention).

Harms and adverse events as defined in the protocol will be reported if the incidence is ≥ 5 % in any of the groups. All serious adverse events will be reported. Harms and adverse events will be reported as number and percentages of participants experiencing the event by system organ class and will be subject to null-hypothesis testing.

Sensitivity analyses will be performed using the potentially biased but conservative non-responder imputation (*baseline observation carried forward* technique)as well as the current best practice multiple imputation procedure[27]*.* Patterns of missing data will be investigated. *A priori*, the less restrictive missing at random (MAR) assumption is considered more reasonable than data missing completely at random (MCAR). Assuming that the data on potential dropouts are MAR, multiple imputation procedures will be applicable to handle missing data for all participants with baseline measurements.

## STATISTICAL METHODS

The analyses of the primary outcome will be performed using a repeated measures analysis of covariance applied using mixed linear modelling [28, 30]. Mean change score of DI will be applied as the dependent outcome variable, whereas group, time, the interaction between time and group, sex, the baseline value of DI are included as independent (fixed) variables and participant identifier as random effect. The potentially biased *per-protocol* population analysis will be adjusted for putative confounders: sex, age, diabetes duration, baseline maximal oxygen consumption. If the global test indicates between-group differences (H0,DCON = H0,MED = H0,HED = H0,CON; p ≤ 0.1), pairwise between-group differences, in the order described above, will be explored. The same statistical method will be applied to the other continues outcomes.

The assumptions for using the linear models will be checked to confirm normal distribution of the residuals and the homogeneity of the variance (standardized residuals vs. the predicted values). Variables not meeting the model assumptions will be transformed using appropriate transformations. If no suitable transformation is identified, the median change with interquartile ranges will be reported and testing will be performed using suitable non-parametric statistical tests (e.g. quantile regression).

Dichotomous outcomes (i.e. discontinuation, reduction or intensification of medications according to the predefined treatment algorithm) at 16 weeks follow-up compared to baseline) will be analyzed using logistic regression. If the dichotomous outcome data are sparse, the asymptotic results can be unreliable; therefore, Fisher's exact tests will be used to calculate the exact probability of the possible (2×4) tables allowing estimation of the Wald-test-associated variance, which corresponds to the ratio of its estimate (log-odds ratio [OR]) to its standard error. By default, no imputations will be used (statistical or otherwise) for the analysis, but robustness will be assessed via sensitivity analyses which evaluate missing data to explore the effect of departures from the assumption made in the main analysis (missing at random).

Statistical code for the primary analysis

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

mixed dDI i.group##i.time DI\_0 i.sex ||ID:,

contrast i.group##i.time (note: omnibus test)

pwcompare i.group##i.time (note: pairwise comparisons if the omnibus test allows)

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

The variable *dDI* is the change in late-phase disposition index from baseline (0 weeks) to end follow-up (16 weeks). *Group* is the treatment variable; *sex* describes the sex of the participants and *DI\_0* is the baseline late-phase disposition index. The model includes treatment (group, 4 levels), time (2 levels), sex (2 levels), and the possible interaction between treatment and time (8 levels) as fixed effects, with the baseline value of the relevant variable as a covariate.

## DEVIATIONS FROM THE ORIGINAL PROTOCOL

Due to new data on the effects of medical discontinuation, following protocol changes were made prior to initiation of the study (Date for amendment Dec. 18th, 2018);

* Complete medical discontinuation upon inclusion was abandoned and excluded from the *per-protocol definition*.

Due to a slow recruitment rate and exclusion of a clinically relevant group of potential participants, we modified the following eligibility criteria (Date for amendment Sep. 2nd, 2019);

* “No known lung disease” was changed to “No lung disease, other than asthma that can be managed with beta2-agonists and does not exhibit seasonal variation.
* “No known thyroid disease” was changed to “No changes in hypothyroid disease treatment within the last 3 three months prior to enrolment”
* “No known liver disease” was changed to “No known liver disease - defined as ALAT or ASAT elevated three times above upper limit.”
* “No known autoimmune disease” was changed to “No psoriasis disease requiring systemic treatment or cutaneous elements bigger than a total area of 25 cm2”
* “No diagnose of depression or treatment with anti-depressive medication, ongoing or within the last three months before enrolment” was changed to “No changes in symptoms or anti-depressive medication three months prior to enrolment.”
* ” Protein or glucose in the urine at pre-screening” was changed to “Macroalbuminuria at pre-screening”
* “No biochemical sign of other major diseases” was changed to “Biochemical sign of other major diseases”

The majority of participants were not able to attend the 4- and 12-week visits following an overnight fast, thus fasting blood sampling at these timepoint were abandoned.

Change from 2-hour to 1-hour hyperglycemia + GLP-1 infusion as we were not able to maintain

hyperglycemia and with excessive high coefficients of variation.

In the event of malfunctioning heart rate monitoring, the participant was carefully instructed to train in accordance to the Borg scale corresponding to target heart rate zones (i.e. %HRmax) in harmony with the specific training program[31].

Six participants have had their intervention prolonged 3 weeks in order to ensure that they were no longer infected or infectious. The participant group distribution consisted of 1 CON, 2 DCON, 2 MED and 1 HED.

# IMPLEMENTATION OF THE SAP

Upon SAP approval by and signatures of the writing committee, the statistical analysis plan will published at The Centre for Physical Activity website ([www.aktivsundhed.dk](http://www.aktivsundhed.dk)) prior to commencing any statistical analyses.

# EXPECTED WRITING COMMITTEE

Grit E. Legaard\*, Mark P.P. Lyngbæk\*, Kristian Karstoft, Nina S. Nielsen, Camilla Feineis, Sebastian L. Bennetsen, Ulrikke Nystrup, Benedikte Liebetrau, Katja Thomsen, Jan Christian Brønd, Martin Østergaard, Beckey Trinh, Thomas Solomon, Gerrit Van Hall, Jens J. Holst, Bolette Hartmann, Robin Christensen, Thomas P. Almdal, Bente. K. Pedersen, Mathias Ried-Larsen

\*The authors contributed equally to the work.

Acknowledgements

We would like to thank the current and former CFAS and Center for Diabetes Municipality of Copenhagen employees; Villads Rasmussen, Cecilie F. Brinkløv, Anette Blom Nielsen, Katja Kofoed, Nana Møgelberg, Indzi Hamidovski for the technical and administrative support in the data collection and delivering the intervention.

# EXPECTED OUTLINE OF THE REPORT

The study report will be aimed at a clinical journal, thus the report will contain 3500-4000 words and 4 to 6 main figures and tables depending on the journal.

## OVERVIEW OF CONTENT (Unformatted tables with specific variables are placed at the end of the text)

## TABLES (In paper)

Table 1 Baseline characteristics

Table 2 Within group changes in the primary and major secondary outcomes

Table 3 Pairwise comparisons of the change in the primary outcome and major secondary outcomes

Table 4 Within group changes in other outcomes reflecting underlying mechanisms of β cell function

Table 5 Pairwise comparisons of the change in other outcomes reflecting underlaying mechanisms of β cell function

## FIGURES (In paper)

Figure 1: Table of graphs (2x3 panel) depicting the within-group change (baseline to 16 weeks) in the primary outcome and major secondary outcomes. Data are presented as least-squares-means (bar charts overlaid with individual values) with 95% confidence intervals.

Figure 2a: Change in late phase disposition index (primary outcome) by group

Figure 2b: Change in late phase insulin sensitivity index by group

Figure 2c: Change in late phase insulin secretion rate by group

Figure 2d: Change in oral disposition index by group

Figure 2e: Change in oral insulin sensitivity index by group

Figure 2f: Change in oral insulinogenic index by group

## ONLINE ONLY (Tables)

* eTable 1 Self-reported adherence to diet
* eTabel 2 Self-reported adherence to pharmacological treatmentand management
* eTable 3 Free-living physical activity
* eTable 4 Intensity and duration in aerobic training. Intensity measured as %HRmax in intervention in MED and HED group. Intensity is reported as duration in moderate intensity (60-79% HRmax) and duration in high intensity (80-100% HRmax).
* eTable 5 Resistance training in the large muscle groups. Intensity measured as repetitions in reserve in resistance training intervention in MED and HED group.
* eTable 6 Volume load (tonnage) in resistance training in the large muscle groups. Volume load measured as tonnage (kg x repetitions x sets).
* eTable 7 Exercise modification and causes in aerobic training in MED and HED group.
* eTable 8 Exercise modification and causes in resistance training in MED and HED group.
* eTabel 9 Adherence for aerobic and resistance training in MED and HED group.
* eTable 10 Coefficient of variation and precision during the hyperglycemic clamp
* eTable 11 Sensitivity analyses - Pairwise comparisons of the change in the primary and major outcomes
* eTable 12 Baseline values and within group changes (0-16 weeks) in the primary outcome and other secondary outcomes derived from the hyperglycemic clamp
* eTable 13 Other Pairwise comparisons of secondary outcomes derived from the mixed meal tolerance test
* eTable 14 Baseline values and within group changes (0-16 weeks) cardiometabolic, body composition and fitness
* eTable 15 Pairwise comparisons of the change in cardiometabolic, body composition and fitness
* eTable 16 Adverse events after randomization

## ONLINE ONLY (Figures)

eFigure 1: Flow of participants

* eFigure 2: Figure describing the pre-defined algorithms for pharmacological management of blood glucose, blood pressure and blood lipids including therapeutic targets.
* eFigure 3: Table of graphs describing the insulin secretion rates (least-squares-means, concentration on the y-axis) across the clamp (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)
* eFigure 4: Table of graphs describing the glucose infusion rates (least-squares-means, concentration on the y-axis) across the clamp (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)
* eFigure 5: Table of graphs describing the GLP-1 (least-squares-means, concentration on the y-axis) across the hyperglycemic clamp (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)
* eFigure 6: Table of graphs describing the glucose (least-squares-means, concentration on the y-axis) response during the mixed meal tolerance test (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)
* eFigure 7: Table of graphs describing the insulin (least-squares-means, concentration on the y-axis) response during the mixed meal tolerance test (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)
* eFigure 8: Table of graphs describing the c-peptide (least-squares-means, concentration on the y-axis) response during the mixed meal tolerance test (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)
* eFigure 9: Table of graphs describing the GLP-1 (least-squares-means, concentration on the y-axis) response during the mixed meal tolerance test (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)
* eFigure 10: Table of graphs describing the GIP (least-squares-means, concentration on the y-axis) response during the mixed meal tolerance test (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)
* eFigure 11: Table of graphs describing the paracetamol (least-squares-means, concentration on the y-axis) response during the mixed meal tolerance test (time in minutes on x-axis) by group (1a, 1b, 1c, 1d) with pre and post values and standard errors in the same graph (overlay graphs)

# REFERENCES

1. Taylor, R., et al., *Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for beta Cell Recovery.* Cell Metab, 2018. **28**(4): p. 547-556 e3.

2. Johansson, K., M. Neovius, and E. Hemmingsson, *Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials.* The American Journal of Clinical Nutrition, 2013. **99**(1): p. 14-23.

3. Lean, M.E.J., et al., *Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.* Lancet Diabetes Endocrinol, 2019. **7**(5): p. 344-355.

4. Karstoft, K., et al., *Mechanisms behind the superior effects of interval vs continuous training on glycaemic control in individuals with type 2 diabetes: a randomised controlled trial.* Diabetologia, 2014. **57**(10): p. 2081-93.

5. Dela, F., et al., *Physical training may enhance beta-cell function in type 2 diabetes.* Am J Physiol Endocrinol Metab, 2004. **287**(5): p. E1024-31.

6. Rogers, M.A., et al., *Improvement in glucose tolerance after 1 wk of exercise in patients with mild NIDDM.* Diabetes Care, 1988. **11**(8): p. 613-8.

7. Krotkiewski, M., et al., *The effects of physical training on insulin secretion and effectiveness and on glucose metabolism in obesity and type 2 (non-insulin-dependent) diabetes mellitus.* Diabetologia, 1985. **28**(12): p. 881-90.

8. Eriksen, L., et al., *Comparison of the effect of multiple short-duration with single long-duration exercise sessions on glucose homeostasis in type 2 diabetes mellitus.* Diabetologia, 2007. **50**(11): p. 2245-53.

9. Hannon, T.S., et al., *Review of methods for measuring beta-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium.* Diabetes Obes Metab, 2018. **20**(1): p. 14-24.

10. Malin, S.K., et al., *Pancreatic beta-cell function increases in a linear dose-response manner following exercise training in adults with prediabetes.* Am J Physiol Endocrinol Metab, 2013. **305**(10): p. E1248-54.

11. Umpierre, D., et al., *Volume of supervised exercise training impacts glycaemic control in patients with type 2 diabetes: a systematic review with meta-regression analysis.* Diabetologia, 2013. **56**(2): p. 242-51.

12. Boule, N.G., et al., *Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus.* Diabetologia, 2003. **46**(8): p. 1071-81.

13. Sigal, R.J., et al., *Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial.* Ann Intern Med, 2007. **147**(6): p. 357-69.

14. Church, T.S., et al., *Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial.* JAMA, 2010. **304**(20): p. 2253-62.

15. Curran, M., et al., *The benefits of physical exercise for the health of the pancreatic beta-cell: a review of the evidence.* Exp Physiol, 2020.

16. Action to Control Cardiovascular Risk in Diabetes Study, G., et al., *Effects of intensive glucose lowering in type 2 diabetes.* N Engl J Med, 2008. **358**(24): p. 2545-59.

17. Group, A.C., et al., *Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.* N Engl J Med, 2008. **358**(24): p. 2560-72.

18. Duckworth, W., et al., *Glucose control and vascular complications in veterans with type 2 diabetes.* N Engl J Med, 2009. **360**(2): p. 129-39.

19. Reusch, J.E. and J.E. Manson, *Management of Type 2 Diabetes in 2017: Getting to Goal.* JAMA, 2017. **317**(10): p. 1015-1016.

20. Hemmingsen, B., et al., *Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.* BMJ, 2011. **343**: p. d6898.

21. *Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.* Lancet, 1998. **352**(9131): p. 837-53.

22. Lipska, K.J. and H.M. Krumholz, *Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?* JAMA, 2017. **317**(10): p. 1017-1018.

23. Umpierre, D., et al., *Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis.* JAMA, 2011. **305**(17): p. 1790-9.

24. Avery, L., et al., *Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions.* Diabetes Care, 2012. **35**(12): p. 2681-9.

25. Boule, N.G., et al., *Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials.* JAMA, 2001. **286**(10): p. 1218-27.

26. Lyngbaek, M.P.P., et al., *The effects of different doses of exercise on pancreatic beta-cell function in patients with newly diagnosed type 2 diabetes: study protocol for and rationale behind the "DOSE-EX" multi-arm parallel-group randomised clinical trial.* Trials, 2021. **22**(1): p. 244.

27. White, I.R., et al., *Strategy for intention to treat analysis in randomised trials with missing outcome data.* BMJ, 2011. **342**: p. d40.

28. Detry, M.A. and R.J. Lewis, *The intention-to-treat principle: how to assess the true effect of choosing a medical treatment.* JAMA, 2014. **312**(1): p. 85-6.

29. Dmitrienko, A. and R.B. D'Agostino, Sr., *Multiplicity Considerations in Clinical Trials.* N Engl J Med, 2018. **378**(22): p. 2115-2122.

30. Atlas, C., et al., *Reconstruction of hadronic decay products of tau leptons with the ATLAS experiment.* Eur Phys J C Part Fields, 2016. **76**(5): p. 295.

31. Scherr, J., et al., *Associations between Borg's rating of perceived exertion and physiological measures of exercise intensity.* Eur J Appl Physiol, 2013. **113**(1): p. 147-55.

# UNFORMATTED TABLES WITH INTENDED CONTENT

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 1 Baseline characteristics** | | | | | |
|  | CON | DCON | MED | HED | Total |
| Age (years) |  |  |  |  |  |
| Sex (N (%) female) |  |  |  |  |  |
| Type 2 diabetes duration (years) |  |  |  |  |  |
| Glycemic control |  |  |  |  |  |
| HbA1c (mmol/mol) |  |  |  |  |  |
| HbA1c (%) |  |  |  |  |  |
| Fasting glucose (mmol/l) |  |  |  |  |  |
| Fasting insulin (pmol/l) |  |  |  |  |  |
| Fasting C-peptide (pmol/l) |  |  |  |  |  |
| Lipids |  |  |  |  |  |
| Low Density lipoprotein |  |  |  |  |  |
| Fasting triglycerides |  |  |  |  |  |
| Blood pressure |  |  |  |  |  |
| Systolic (mmHg) |  |  |  |  |  |
| Diastolic (mmHg) |  |  |  |  |  |
|  |  |  |  |  |  |
| Glucose-lowering medication, N (%) |  |  |  |  |  |
| None |  |  |  |  |  |
| Biguanide |  |  |  |  |  |
| Biguanide **+** SGLT2i **or** DPP4i |  |  |  |  |  |
| Biguanide + SGLT2i **+** DPP4i |  |  |  |  |  |
| Lipid-lowering medication, No (%) |  |  |  |  |  |
| None |  |  |  |  |  |
| Statin |  |  |  |  |  |
| Blood pressure lowering medication, No (%) |  |  |  |  |  |
| None |  |  |  |  |  |
| ARB **or** ACEi |  |  |  |  |  |
| ARB **or** ACEi + Thiazide **or** CCB |  |  |  |  |  |
| ARB **or** ACEi + Thiazide + CCB |  |  |  |  |  |
| Physical function |  |  |  |  |  |
| Absolute VO2 max (ml/min) |  |  |  |  |  |
| Relative VO2 max (ml/kg/min) |  |  |  |  |  |
| Watt max (W/kg) |  |  |  |  |  |
| 1 RM chest press (kg) |  |  |  |  |  |
| 1 RM leg extension (kg) |  |  |  |  |  |
| Body composition |  |  |  |  |  |
| Body weight (kg) |  |  |  |  |  |
| BMI (kg/m2) |  |  |  |  |  |
| Diet |  |  |  |  |  |
| Energy intake (kcal/day) |  |  |  |  |  |
| Physical activity level |  |  |  |  |  |
| Moderate and vigorous physical activity (hours/day) |  |  |  |  |  |
| Stepping (steps/day) |  |  |  |  |  |
| Sitting (hours/day) |  |  |  |  |  |
| Hyperglycemic clamp |  |  |  |  |  |
| Basal |  |  |  |  |  |
| Mean insulin secretion rate |  |  |  |  |  |
| Glucose Ra (mg \* kg−1 \* min−1) |  |  |  |  |  |
| Glucose Rd (mg \* kg−1 \* min−1) |  |  |  |  |  |
| Early phase hyperglycemia |  |  |  |  |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  |  |
| Mean insulin secretion rate |  |  |  |  |  |
| Peak insulin secretion rate |  |  |  |  |  |
|  |  |  |  |  |  |
| **Table 1 cont’d** |  |  |  |  |  |
| Steady state hyperglycemia |  |  |  |  |  |
| Late phase disposition index |  |  |  |  |  |
| Late phase insulin sensitivity index |  |  |  |  |  |
| Late phase insulin secretion rate |  |  |  |  |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  |  |
| Peak insulin secretion rate |  |  |  |  |  |
| Glucose Ra (mg \* kg−1 \* min−1) |  |  |  |  |  |
| Glucose Rd (mg \* kg−1 \* min−1) |  |  |  |  |  |
| Hyperglycemia and GLP-1 |  |  |  |  |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  |  |
| Mean insulin secretion rate |  |  |  |  |  |
| Peak insulin secretion rate |  |  |  |  |  |
| Hyperglycemia, GLP-1 and Arginine |  |  |  |  |  |
| Mean insulin secretion rate |  |  |  |  |  |
| Peak insulin secretion rate |  |  |  |  |  |
| Mixed meal tolerance test |  |  |  |  |  |
| 0-30 min |  |  |  |  |  |
| tAUC glucose |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |
| 0-120 min |  |  |  |  |  |
| Oral disposition index |  |  |  |  |  |
| Oral insulin sensitivity index |  |  |  |  |  |
| tAUC glucose |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |
| Data are presented as mean (SD) or median (IQR). CON, control group, DCON: Diet control group: MED: Moderate volume exercise, HED: High volume exercise, HbA1c: glycated hemoglobin A1c, LDL: low-density lipoprotein, BMI: body mass index (calculated as weight in kilograms divided by height in meters squared). SLGT2i: selective sodium glucose co-transporter 2 inhibitors*,* DPP4i*:* dipeptidyl peptidase 4 inhibitors, ARB: angiotensin II receptor blockers, ACEi: angiotensin converting enzyme inhibitors, CCB: calcium channel blockers. Ra: Rate of appearance, Rd: Rate of disappearance, GIR: Glucose infusion rate | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 2 Within-group changes from baseline to 16-week follow-up in the primary and major secondary outcomes | | | | | | | | | | |
|  | CON | | DCON | | MED | | | HED | |
|  | Change | 95% CI | Change | 95% CI | Change | 95% CI | Change | | 95% CI |
|  |  |  |  |  |  |  |  | |  |
| Primary outcome |  |  |  |  |  |  |  | |  |
| Late-phase Disposition index |  |  |  |  |  |  |  | |  |
|  |  |  |  |  |  |  |  | |  |
| Major Secondary outcomes |  |  |  |  |  |  |  | |  |
| Late-phase insulin secretion rate |  |  |  |  |  |  |  | |  |
| Late-phase insulin sensitivity |  |  |  |  |  |  |  | |  |
| Oral disposition index |  |  |  |  |  |  |  | |  |
| Oral insulin sensitivity index |  |  |  |  |  |  |  | |  |
| Oral insulinogenic index |  |  |  |  |  |  |  | |  |
|  |  |  |  |  |  |  |  | |  |
| Data are least-squares means. CI: confidence intervals, CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 3 Pairwise comparisons of the change in the primary outcome and major secondary outcomes | | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | |
|  | HED vs. CON | |  | MED vs. CON | |  | DCON vs. CON | |  | HED vs. DCON | |  | MED vs. DCON | |  | HED vs. MED | | P |
|  | MD | 95% CI |  | MD | 95% CI |  | MD | 95% CI |  | MD | 95% CI |  | MD | 95% CI |  | MD | 95% CI |  |
| Primary outcome |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Late-phase Disposition index |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Major Secondary outcomes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Insulin secretion rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Insulin sensitivity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral disposition index |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral insulin sensitivity index |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral insulinogenic index |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| MD: Mean difference, CI: confidence intervals. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise | | | | | | | | | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 4 Within-group changes from baseline to 16-week follow-up in in other outcomes reflecting underlaying mechanisms of beta-cell function | | | | | | | | | | |
|  | CON | | DCON | | MED | | | HED | |
|  | Change | 95% CI | Change | 95% CI | Change | 95% CI | Change | | 95% CI |
| Basal |  |  |  |  |  |  |  | |  |
| Mean insulin secretion rate |  |  |  |  |  |  |  | |  |
| Glucose Ra (mg \* kg−1 \* min−1) |  |  |  |  |  |  |  | |  |
| Glucose Rd (mg \* kg−1 \* min−1) |  |  |  |  |  |  |  | |  |
| Early state hyperglycemia |  |  |  |  |  |  |  | |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  |  |  |  | |  |
| Mean insulin secretion rate |  |  |  |  |  |  |  | |  |
| Peak insulin secretion rate |  |  |  |  |  |  |  | |  |
| Steady state hyperglycemia |  |  |  |  |  |  |  | |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  |  |  |  | |  |
| Peak insulin secretion rate |  |  |  |  |  |  |  | |  |
| Glucose Ra (mg \* kg−1 \* min−1) |  |  |  |  |  |  |  | |  |
| Glucose Rd (mg \* kg−1 \* min−1) |  |  |  |  |  |  |  | |  |
| Hyperglycemia and GLP-1 |  |  |  |  |  |  |  | |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  |  |  |  | |  |
| Mean insulin secretion rate |  |  |  |  |  |  |  | |  |
| Peak insulin secretion rate |  |  |  |  |  |  |  | |  |
| Hyperglycemia, GLP-1 and Arginine |  |  |  |  |  |  |  | |  |
| Mean insulin secretion rate |  |  |  |  |  |  |  | |  |
| Peak insulin secretion rate |  |  |  |  |  |  |  | |  |
|  |  |  |  |  |  |  |  | |  |
| 0-30 min |  |  |  |  |  |  |  | |  |
| tAUC glucose |  |  |  |  |  |  |  | |  |
| tAUC C-peptide |  |  |  |  |  |  |  | |  |
| tAUC insulin |  |  |  |  |  |  |  | |  |
| tAUC GLP-1total |  |  |  |  |  |  |  | |  |
| tAUC GLP-1active |  |  |  |  |  |  |  | |  |
| tAUC GIPtotal |  |  |  |  |  |  |  | |  |
| tAUC paracetamol |  |  |  |  |  |  |  | |  |
| 0-120 min |  |  |  |  |  |  |  | |  |
| tAUC glucose |  |  |  |  |  |  |  | |  |
| tAUC C-peptide |  |  |  |  |  |  |  | |  |
| tAUC insulin |  |  |  |  |  |  |  | |  |
| tAUC GLP-1total |  |  |  |  |  |  |  | |  |
| tAUC GLP-1active |  |  |  |  |  |  |  | |  |
| tAUC GIPtotal |  |  |  |  |  |  |  | |  |
| tAUC paracetamol |  |  |  |  |  |  |  | |  |
|  |  |  |  |  |  |  |  | |  |
| Data are least-squares means. CI: confidence intervals, CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, GIR: glucose infusion rate, Ra: Rate of appearance, Rd: Rate of disappearance: GLP-1: Glucagon-like-peptide 1, GIP: Gastric inhibitory polypeptide, tAUC: Total area under the curve | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 5 Pairwise comparisons of the change in other outcomes reflecting underlying mechanisms of beta-cell function | | | | | | | | | | | | | |
|  | HED vs. CON | | MED vs. CON | | DCON vs. CON | | | HED vs. DCON | | MED vs. DCON | | HED vs. MED | |
|  | MD | 95% CI | MD | 95% CI | | MD | 95% CI | MD | 95% CI | MD | 95% CI | MD | 95% CI |
|  | Hyperglycemic clamp | | | | | | | | | | | | |
| Basal |  | |  | |  | | |  | |  | |  | |
| Mean insulin secretion rate |  |  |  |  | |  |  |  |  |  |  |  |  |
| Glucose Ra (mg \* kg−1 \* min−1) |  |  |  |  | |  |  |  |  |  |  |  |  |
| Glucose Rd (mg \* kg−1 \* min−1) |  |  |  |  | |  |  |  |  |  |  |  |  |
| Early state hyperglycemia |  |  |  |  | |  |  |  |  |  |  |  |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  | |  |  |  |  |  |  |  |  |
| Mean insulin secretion rate |  |  |  |  | |  |  |  |  |  |  |  |  |
| Peak insulin secretion rate |  |  |  |  | |  |  |  |  |  |  |  |  |
| Steady state hyperglycemia |  |  |  |  | |  |  |  |  |  |  |  |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  | |  |  |  |  |  |  |  |  |
| Peak insulin secretion rate |  |  |  |  | |  |  |  |  |  |  |  |  |
| Glucose Ra (mg \* kg−1 \* min−1) |  |  |  |  | |  |  |  |  |  |  |  |  |
| Glucose Rd (mg \* kg−1 \* min−1) |  |  |  |  | |  |  |  |  |  |  |  |  |
| Hyperglycemia and GLP-1 |  |  |  |  | |  |  |  |  |  |  |  |  |
| Mean GIR (mg \* kg−1 \* min−1) |  |  |  |  | |  |  |  |  |  |  |  |  |
| Mean insulin secretion rate |  |  |  |  | |  |  |  |  |  |  |  |  |
| Peak insulin secretion rate |  |  |  |  | |  |  |  |  |  |  |  |  |
| Hyperglycemia, GLP-1 and Arginine |  |  |  |  | |  |  |  |  |  |  |  |  |
| Mean insulin secretion rate |  |  |  |  | |  |  |  |  |  |  |  |  |
| Peak insulin secretion rate |  |  |  |  | |  |  |  |  |  |  |  |  |
|  | Mixed meal tolerance test | | | | | | | | | | | | |
| 0-30 min |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC glucose |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  | |  |  |  |  |  |  |  |  |
| 0-120 min |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC glucose |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  | |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  | |  |  |  |  |  |  |  |  |
| MD: Mean difference, CI: confidence intervals. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, GIR: glucose infusion rate, Ra: Rate of appearance, Rd: Rate of disappearance: GLP-1: Glucagon-like-peptide 1, GIP: Gastric inhibitory polypeptide, tAUC: Total area under the curve | | | | | | | | | | | | | |

ONLINE ONLY

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 1 Adherence to diet | | | | | | | |  |  |
|  | Baseline (N=) | Week 4 (N=) | % adherence | Week 12 (N=) | % adherence | Week 16 (N=) | % adherence | % adherence after randomization | Mean reduction after randomization (% from baseline) |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Total energy intake (Kcal/kg/day) |  |  |  |  |  |  |  |  |  |
| CON |  |  |  |  |  |  |  |  |  |
| DCON |  |  |  |  |  |  |  |  |  |
| MED |  |  |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Total carbohydrate (% of total energy intake) |  |  |  |  |  |  |  |  |  |
| CON |  |  |  |  |  |  |  |  |  |
| DCON |  |  |  |  |  |  |  |  |  |
| MED |  |  |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Fiber (% of total energy intake) |  |  |  |  |  |  |  |  |  |
| CON |  |  |  |  |  |  |  |  |  |
| DCON |  |  |  |  |  |  |  |  |  |
| MED |  |  |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Total fat (% of total energy intake) |  |  |  |  |  |  |  |  |  |
| CON |  |  |  |  |  |  |  |  |  |
| DCON |  |  |  |  |  |  |  |  |  |
| MED |  |  |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Saturated fat (% of total energy intake) |  |  |  |  |  |  |  |  |  |
| CON |  |  |  |  |  |  |  |  |  |
| DCON |  |  |  |  |  |  |  |  |  |
| MED |  |  |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Protein (% of total energy intake) |  |  |  |  |  |  |  |  |  |
| CON |  |  |  |  |  |  |  |  |  |
| DCON |  |  |  |  |  |  |  |  |  |
| MED |  |  |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Alcohol (% of total energy intake) |  |  |  |  |  |  |  |  |  |
| CON |  |  |  |  |  |  |  |  |  |
| DCON |  |  |  |  |  |  |  |  |  |
| MED |  |  |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Data are mean and standard deviation or median and interquartile range. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTabel 2 self-reported adherence to pharmacological treatmenta and management | | | | | | | | | | | | | | | | |
|  | Baseline |  |  |  | Week 4 |  |  |  | Week 12 |  |  |  | Week 16 |  |  |  |
|  | CON | DCON | MED | HED | CON | DCON | MED | HED | CON | DCON | MED | HED | CON | DCON | MED | HED |
| Proportion of participants attending consultation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Self-reported adherence to Glucose-lowering medication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Several times per week |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Once a week |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Several times per month |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Once a month |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Never |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Not relevant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Does not take prescribed medication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Missing values |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Self-reported adherence to blood pressure-lowering medication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Several times per week |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Once a week |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Several times per month |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Once a month |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Never |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Not relevant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Does not take prescribed medication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Missing values |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Self-reported adherence to lipid-lowering medication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Several times per week |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Once a week |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Several times per month |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Once a month |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Never |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Not relevant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Does not take prescribed medication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Missing values |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Glucose-lowering medication, N (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| None |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Biguanide |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Biguanide **+** SGLT2i **or** DPP4i |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Biguanide + SGLT2i **+** DPP4i |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lipid-lowering medication, No (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| None |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Statin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Blood pressure lowering medication, No (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| None |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ARB **or** ACEi |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ARB **or** ACEi + Thiazide **or** CCB |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ARB **or** ACEi + Thiazide + CCB |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Data presented as N (%)  There were five adherence categories in relation to how often the participants would forget to take their medicine: 1) several times per week 2) once a week 3) several times per month 4) once a month 5) never.  Adherence (%) in these categories is calculated as follows: Total N - (does not take the prescribed medicine + numbers of participants with no medication + missing values) since adherence is calculated based on the participants that are prescribed medication and taking the medication. Not the total number of participants (N).  aHow often does the participant forget the medication | | | | | | | | | | | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| eTable 3 Free-living physical activity | | | | |
|  | Baseline (N=) | Week 4 (N=) | Week 12 (N=) | Week 16 (N=) |
|  |  |  |  |  |
| Valid days (N) |  |  |  |  |
| CON |  |  |  |  |
| DCON |  |  |  |  |
| MED |  |  |  |  |
| HED |  |  |  |  |
|  |  |  |  |  |
| Wear time (hours/day) |  |  |  |  |
| CON |  |  |  |  |
| DCON |  |  |  |  |
| MED |  |  |  |  |
| HED |  |  |  |  |
|  |  |  |  |  |
| Total physical activity (counts per minute) |  |  |  |  |
| CON |  |  |  |  |
| DCON |  |  |  |  |
| MED |  |  |  |  |
| HED |  |  |  |  |
|  |  |  |  |  |
| MVPA (min/day) |  |  |  |  |
| CON |  |  |  |  |
| DCON |  |  |  |  |
| MED |  |  |  |  |
| HED |  |  |  |  |
|  |  |  |  |  |
| Sitting time (min/day) |  |  |  |  |
| CON |  |  |  |  |
| DCON |  |  |  |  |
| MED |  |  |  |  |
| HED |  |  |  |  |
|  |  |  |  |  |
| Stepping (steps/day) |  |  |  |  |
| CON |  |  |  |  |
| DCON |  |  |  |  |
| MED |  |  |  |  |
| HED |  |  |  |  |
|  |  |  |  |  |
| Data are mean and standard deviation or median and interquartile range. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, MVPA: Moderate and vigorous physical activity | | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 4 Intensity and duration in aerobic training | | | | | | | |
| Intensity (internal and external load) in aerobic training | | | | | | | |
| Familiarization week 1-2 | Average %HRmax, N (%) | | Number of minutes 60-79% HRmax, (N=) | Number of minutes 80-100% HRmax, (N=) | Minutes spent in 80-100% HRmax, N (%) | Average watt, (N=) |  |
| MED |  | |  |  |  |  |  |
| HED |  | |  |  |  |  |  |
| Week 3-10 | Average %HRmax, N (%) | | Number of minutes 60-79% HRmax, (N=) | Number of minutes 80-100% HRmax, (N=) | Minutes spent in 80-100% HRmax, N (%) | Average watt, (N=) | Increase in average watt from week 1-2 to 3-10 N (%) |
| MED |  | |  |  |  |  |  |
| HED |  | |  |  |  |  |  |
| Week 11-16 | Average %HRmax, N (%) | | Number of minutes 60-79% HRmax, (N=) | Number of minutes 80-100% HRmax, (N=) | Minutes spent in 80-100% HRmax, N (%) | Average watt, (N=) | Increase in average watt from week 3-10 to week 11-16 N (%) |
| MED |  | |  |  |  |  |  |
| HED |  | |  |  |  |  |  |
| Week 3-16 | Number of minutes 60-79% HRmax, (N=) | | Number of minutes 80-100% HRmax, (N=) | Number of minutes within target %HRmax, N (%) | Minutes spent in 80-100% HRmax, N (%) | Average watt, (N=) | Increase in average watt from week 3 to week 16, N (%) |
| MED |  | |  |  |  |  |  |
| HED |  | |  |  |  |  |  |
| Duration of aerobic training | | | | | | | |
| Familiarization week 1-2 | Number of minutes prescribed pr. week, (N=) | Number of minutes performed pr week, (N=) | | Number of minutes completed from prescribed, N (%) | Number of minutes performed within target %HRmax, N (%) | Number of minutes pr. sessions, (N=) | Number of sessions pr. week, (N=) |
| MED |  |  | |  |  |  |  |
| HED |  |  | |  |  |  |  |
| Week 3-10 | Number of minutes prescribed pr. week, (N=) | Number of minutes performed pr week, (N=) | | Number of minutes completed from prescribed, N (%) | Number of minutes performed within target %HRmax, N (%) | Number of minutes pr. sessions (N=) | Number of sessions pr. week, (N=) |
| MED |  |  | |  |  |  |  |
| HED |  |  | |  |  |  |  |
| Week 11-16 | Number of minutes prescribed pr. week, (N=) | Number of minutes performed pr week, (N=) | | Number of minutes completed from prescribed, N (%) | Number of minutes performed within target %HRmax, N (%) | Number of minutes pr. sessions (N=) | Number of sessions pr. week, (N=) |
| MED |  |  | |  |  |  |  |
| HED |  |  | |  |  |  |  |
| Week 3-16 | Number of minutes prescribed pr. week, (N=) | Number of minutes performed pr week, (N=) | | Number of minutes completed from prescribed, N (%) | Number of minutes performed within target %HRmax, N (%) | Number of minutes pr. sessions (N=) | Number of sessions pr. week, (N=) |
| MED |  |  | |  |  |  |  |
| HED |  |  | |  |  |  |  |
| Data are mean and standard deviation or median and interquartile range. HRmax: Maximum heart rate, MED: Moderate volume exercise, HED: High volume exercise | | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| eTable 5 Resistance training in the large muscle groups | | | | |
| Familiarization week 1-2 | Number of sets prescribed pr. week, (N=) | Number of sets performed pr. week, (N=) | Number of sets completed from prescribed, N (%) | Number of sets performed within target RIR, N (%) |
| MED |  |  |  |  |
| Leg press |  |  |  |  |
| Leg extension |  |  |  |  |
| Leg curl |  |  |  |  |
| Chest press |  |  |  |  |
| Back row |  |  |  |  |
| Total |  |  |  |  |
| HED |  |  |  |  |
| Leg press |  |  |  |  |
| Leg extension |  |  |  |  |
| Leg curl |  |  |  |  |
| Chest press |  |  |  |  |
| Back row |  |  |  |  |
| Total |  |  |  |  |
| Week 3-10 | Number of sets prescribed pr. week, (N=) | Number of sets performed pr. week, (N=) | Number of sets completed from prescribed, N (%) | Number of sets performed within target RIR, N (%) |
| MED |  |  |  |  |
| Leg press |  |  |  |  |
| Leg extension |  |  |  |  |
| Leg curl |  |  |  |  |
| Chest press |  |  |  |  |
| Back row |  |  |  |  |
| Total |  |  |  |  |
| HED |  |  |  |  |
| Leg press |  |  |  |  |
| Leg extension |  |  |  |  |
| Leg curl |  |  |  |  |
| Chest press |  |  |  |  |
| Back row |  |  |  |  |
| Total |  |  |  |  |
| Week 11-16 | Number of sets prescribed pr. week, (N=) | Number of sets performed pr. week, (N=) | Number of sets completed from prescribed, N (%) | Number of sets performed within target RIR, N (%) |
| MED |  |  |  |  |
| Leg press |  |  |  |  |
| Leg extension |  |  |  |  |
| Leg curl |  |  |  |  |
| Chest press |  |  |  |  |
| Back row |  |  |  |  |
| Total |  |  |  |  |
| HED |  |  |  |  |
| Leg press |  |  |  |  |
| Leg extension |  |  |  |  |
| Leg curl |  |  |  |  |
| Chest press |  |  |  |  |
| Back row |  |  |  |  |
| Total |  |  |  |  |
| Week 3-16 | Number of sets prescribed pr. week, (N=) | Number of sets performed pr. week, (N=) | Number of sets completed from prescribed, N (%) | Number of sets performed within target RIR, N (%) |
| MED |  |  |  |  |
| Leg press |  |  |  |  |
| Leg extension |  |  |  |  |
| Leg curl |  |  |  |  |
| Chest press |  |  |  |  |
| Back row |  |  |  |  |
| Total |  |  |  |  |
| HED |  |  |  |  |
| Leg press |  |  |  |  |
| Leg extension |  |  |  |  |
| Leg curl |  |  |  |  |
| Chest press |  |  |  |  |
| Back row |  |  |  |  |
| Total |  |  |  |  |
| Data are mean and standard deviation or median and interquartile range. RIR: repetitions in reserve, MED: Moderate volume exercise, HED: High volume exercise | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| eTable 6 Volume load (tonnage) in resistance training in the large muscle groups | | | | | | |
| Familiarization week 1-2 | Number of repetitions pr week, (N=) | Number of repetitions pr. set, (N=) | Average kilogram lifted pr. set, (N=) | Number of sets performed pr week, (N=) | Tonnage pr week, (N=) |  |
| MED |  |  |  |  |  |  |
| Leg press |  |  |  |  |  |  |
| Leg extension |  |  |  |  |  |  |
| Leg curl |  |  |  |  |  |  |
| Chest press |  |  |  |  |  |  |
| Back row |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |
| Leg press |  |  |  |  |  |  |
| Leg extension |  |  |  |  |  |  |
| Leg curl |  |  |  |  |  |  |
| Chest press |  |  |  |  |  |  |
| Back row |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |
| Week 3-10 | Number of repetitions pr week, (N=) | Number of repetitions pr. set, (N=) | Average kilogram lifted pr. set, (N=) | Number of sets performed, (N=) | Tonnage pr week, (N=) | Tonnage increase from week 1-2 to week 3-10, N (%) |
| MED |  |  |  |  |  |  |
| Leg press |  |  |  |  |  |  |
| Leg extension |  |  |  |  |  |  |
| Leg curl |  |  |  |  |  |  |
| Chest press |  |  |  |  |  |  |
| Back row |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |
| Leg press |  |  |  |  |  |  |
| Leg extension |  |  |  |  |  |  |
| Leg curl |  |  |  |  |  |  |
| Chest press |  |  |  |  |  |  |
| Back row |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |
| Week 11-16 | Number of repetitions pr week, (N=) | Number of repetitions pr. set, (N=) | Average kilogram lifted pr. set, (N=) | Number of sets performed, (N=) | Tonnage pr week, (N=) | Tonnage increase from week 3-10 to week 11-16, N (%) |
| MED |  |  |  |  |  |  |
| Leg press |  |  |  |  |  |  |
| Leg extension |  |  |  |  |  |  |
| Leg curl |  |  |  |  |  |  |
| Chest press |  |  |  |  |  |  |
| Back row |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |
| Leg press |  |  |  |  |  |  |
| Leg extension |  |  |  |  |  |  |
| Leg curl |  |  |  |  |  |  |
| Chest press |  |  |  |  |  |  |
| Back row |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |
| Week 3-16 | Number of repetitions pr week, (N=) | Number of repetitions pr. set, (N=) | Average kilogram lifted pr. set, (N=) | Number of sets performed, (N=) | Tonnage, (N=) | Tonnage increase from week 3 to week 16, N (%) |
| MED |  |  |  |  |  |  |
| Leg press |  |  |  |  |  |  |
| Leg extension |  |  |  |  |  |  |
| Leg curl |  |  |  |  |  |  |
| Chest press |  |  |  |  |  |  |
| Back row |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |
| Leg press |  |  |  |  |  |  |
| Leg extension |  |  |  |  |  |  |
| Leg curl |  |  |  |  |  |  |
| Chest press |  |  |  |  |  |  |
| Back row |  |  |  |  |  |  |
| Total |  |  |  |  |  |  |
| Data are mean and standard deviation or median and interquartile range. Tonnage: weight (kg) x repetitions x sets, MED: Moderate volume exercise, HED: High volume exercise | | | | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 7 Exercise modification and causes in aerobic training | | | | | | | |
| Familiarization week 1-2 | Fatigue, (N=) | Musculoskeletal discomfort, (N=) | Motivational, (N=) | Other reasons, (N=) | Missed exercises, (N=) | Number of participants with ≥1 modification (%) | Number of sessions with ≥1 modification (%) |
| MED |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |
| Week 3-10 | Fatigue, (N=) | Musculoskeletal discomfort, (N=) | Motivational, (N=) | Other reasons, (N=) | Missed exercises, (N=) | Number of participants with ≥1 modification (%) | Number of sessions with ≥1 modification (%) |
| MED |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |
| Week 11-16 | Fatigue, (N=) | Musculoskeletal discomfort, (N=) | Motivational, (N=) | Other reasons, (N=) | Missed exercises, (N=) | Number of participants with ≥1 modification (%) | Number of sessions with ≥1 modification (%) |
| MED |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |
| Week 3-16 | Fatigue, (N=) | Musculoskeletal discomfort, (N=) | Motivational, (N=) | Other reasons, (N=) | Missed exercises, (N=) | Number of participants with ≥1 modification (%) | Number of sessions with ≥1 modification (%) |
| MED |  |  |  |  |  |  |  |
| HED |  |  |  |  |  |  |  |
| Data are mean and standard deviation or median and interquartile range. MED: Moderate volume exercise, HED: High volume exercise | | | | | | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 8 Exercise modification and causes in resistance training | | | | | | | | |
| Familiarization week 1-2 | Fatigue, (N=) | Musculoskeletal discomfort, (N=) | Motivational, (N=) | Other reasons, (N=) | Missed exercises, (N=) | Number of participants with ≥1 modification (%) | Number of sessions with ≥1 modification (%) | |
| MED |  |  |  |  |  |  |  | |
| Leg press |  |  |  |  |  |  |  | |
| Leg extension |  |  |  |  |  |  |  | |
| Leg curl |  |  |  |  |  |  |  | |
| Chest press |  |  |  |  |  |  |  | |
| Back row |  |  |  |  |  |  |  | |
| Total |  |  |  |  |  |  |  | |
| HED |  |  |  |  |  |  |  | |
| Leg press |  |  |  |  |  |  |  | |
| Leg extension |  |  |  |  |  |  |  | |
| Leg curl |  |  |  |  |  |  |  | |
| Chest press |  |  |  |  |  |  |  | |
| Back row |  |  |  |  |  |  |  | |
| Total |  |  |  |  |  |  |  | |
| Week 3-10 | Fatigue, (N=) | Musculoskeletal discomfort, (N=) | Motivational, (N=) | Other reasons, (N=) | Missed exercises, (N=) | Number of participants with ≥1 modification (%) | Number of sessions with ≥1 modification (%) | |
| MED |  |  |  |  |  |  |  | |
| Leg press |  |  |  |  |  |  |  | |
| Leg extension |  |  |  |  |  |  |  | |
| Leg curl |  |  |  |  |  |  |  | |
| Chest press |  |  |  |  |  |  |  | |
| Back row |  |  |  |  |  |  |  | |
| Total |  |  |  |  |  |  |  | |
| HED |  |  |  |  |  |  |  | |
| Leg press |  |  |  |  |  |  |  | |
| Leg extension |  |  |  |  |  |  |  | |
| Leg curl |  |  |  |  |  |  |  | |
| Chest press |  |  |  |  |  |  |  | |
| Back row |  |  |  |  |  |  |  | |
| Total |  |  |  |  |  |  |  | |
| Week 11-16 | Fatigue, (N=) | Musculoskeletal discomfort, (N=) | Motivational, (N=) | Other reasons, (N=) | Missed exercises, (N=) | Number of participants with ≥1 modification (%) | Number of sessions with ≥1 modification (%) | |
| MED |  |  |  |  |  |  |  | |
| Leg press |  |  |  |  |  |  |  | |
| Leg extension |  |  |  |  |  |  |  | |
| Leg curl |  |  |  |  |  |  |  | |
| Chest press |  |  |  |  |  |  |  | |
| Back row |  |  |  |  |  |  |  | |
| Total |  |  |  |  |  |  |  | |
| HED |  |  |  |  |  |  |  | |
| Leg press |  |  |  |  |  |  |  | |
| Leg extension |  |  |  |  |  |  |  | |
| Leg curl |  |  |  |  |  |  |  | |
| Chest press |  |  |  |  |  |  |  | |
| Back row |  |  |  |  |  |  |  | |
| Total |  |  |  |  |  |  |  | |
| Week 3-16 | Fatigue, (N=) | Musculoskeletal discomfort, (N=) | Motivational, (N=) | Other reasons, (N=) | Missed exercises, (N=) | Number of participants with ≥1 modification (%) | Number of sessions with ≥1 modification (%) | |
| MED |  |  |  |  |  |  |  | |
| Leg press |  |  |  |  |  |  |  | |
| Leg extension |  |  |  |  |  |  |  | |
| Leg curl |  |  |  |  |  |  |  | |
| Chest press |  |  |  |  |  |  |  | |
| Back row |  |  |  |  |  |  |  | |
| Total |  |  |  |  |  |  |  | |
| HED |  |  |  |  |  |  |  | |
| Leg press |  |  |  |  |  |  |  | |
| Leg extension |  |  |  |  |  |  |  | |
| Leg curl |  |  |  |  |  |  |  | |
| Chest press |  |  |  |  |  |  |  | |
| Back row |  |  |  |  |  |  |  | |
| Total |  |  |  |  |  |  |  | |
| Data are mean and standard deviation or median and interquartile range. MED: Moderate volume exercise, HED: High volume exercise | | | | | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| eTabel 9 Adherence for aerobic and resistance training | | | |
| Familiarization week 1-2 | Aerobic training, N (%) | Resistance training, N (%) | Total training, N (%) |
| MED |  |  |  |
| HED |  |  |  |
| Week 3-10 | Aerobic training, N (%) | Resistance training, N (%) | Total training, N (%) |
| MED |  |  |  |
| HED |  |  |  |
| Week 11-16 | Aerobic training, N (%) | Resistance training, N (%) | Total training, N (%) |
| MED |  |  |  |
| HED |  |  |  |
| Week 3-16 | Aerobic training, N (%) | Resistance training, N (%) | Total training, N (%) |
| MED |  |  |  |
| HED |  |  | Total training, N (%) |
| Total | Aerobic training, N (%) | Resistance training, N (%) |  |
| MED |  |  |  |
| HED |  |  |  |
| Data are mean and standard deviation or median and interquartile range. RIR: repetitions in reserve, MED: Moderate volume exercise, HED: High volume exercise. Adherence: For prescribed aerobic training ≥ 70% of minutes should be within the target heart rate zones.  For prescribed resistance training, ≥ 70% of the sets should be performed at or below the maximum RIR. | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 10 Coefficient of variation and precision during the hyperglycemic clamp | | | | | | | | | | | |
|  | | | | | | | | | | | |
|  | | | | | | | | | | | |
|  | CON |  |  | DCON |  |  | MED |  |  | HED |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | 0 weeks (SD or IQR) | 16 weeks (SD or IQR) |  | 0 weeks (SD or IQR) | 16 weeks (SD or IQR) |  | 0 weeks (SD or IQR) | 16 weeks (SD or IQR) |  | 0 weeks (SD or IQR) | 16 weeks (SD or IQR) |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Coefficient of variance (%) |  |  |  |  |  |  |  |  |  |  |  |
| Basal |  |  |  |  |  |  |  |  |  |  |  |
| Early phase hyperglycemia |  |  |  |  |  |  |  |  |  |  |  |
| Steady phase hyperglycemia |  |  |  |  |  |  |  |  |  |  |  |
| Hyperglycemia + GLP-1 |  |  |  |  |  |  |  |  |  |  |  |
| Hyperglycemia + GLP-1 + Arginine |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Off-target |  |  |  |  |  |  |  |  |  |  |  |
| Steady phase hyperglycemia |  |  |  |  |  |  |  |  |  |  |  |
| Hyperglycemia + GLP-1 |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Data are means and standard deviations/median or interquartile ranges at baseline or follow-up or estimated within-group difference in change from baseline to follow-up with 95% confidence intervals. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, GIR: glucose infusion rate, Ra: Rate of appearance, Rd: Rate of disappearance: GLP-1: Glucagon-like-peptide 1 | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 11 Sensitivity analyses - Pairwise comparisons of the change in the primary outcome and indices of beta-cell function and insulin sensitivity | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | |
|  | HED vs. CON | P-value |  | MED vs. CON | P-value |  | DCON vs. CON | P-value |  | HED vs. DCON | P-value |  | MED vs. DCON | P-value |  | HED vs. MED | P-value |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Per protocol# |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Primary outcome |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Late-phase Disposition index (hyperglycemic clamp) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Major Secondary outcomes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Late-phase insulin sensitivity (hyperglycemic clamp) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Late-phase insulin secretion rate (hyperglycemic clamp) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral disposition index (MMTT) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral insulin sensitivity (MMTT) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral insulinogenic index (MMTT) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Imputation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Primary outcome |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Late-phase Disposition index (hyperglycemic clamp) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Secondary outcomes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Late-phase insulin sensitivity (hyperglycemic clamp) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Late-phase insulin secretion rate (hyperglycemic clamp) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral disposition index (MMTT) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral insulin sensitivity (MMTT) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oral insulinogenic index (MMTT) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Data are estimated mean difference in changes between groups with 95% confidence intervals. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, MMTT: Mixed meal tolerance test  # Adjusted for sex, age, diabetes duration, baseline maximal oxygen consumption | | | | | | | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 12 Baseline values and within group changes (0-16 weeks) for other outcomes from the mixed meal tolerance test derived outcomes | | | | | | | | | | | |
|  | | | | | | | | | | | |
|  | CON | |  | DCON | |  | MED | |  | HED | |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | 0 weeks (SD or IQR) | Change (95% CI) |  | 0 weeks (SD or IQR) | Change (95% CI) |  | 0 weeks (SD or IQR) | Change (95% CI) |  | 0 weeks (SD or IQR) | Change (95% CI) |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| 0-15 min |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Incremental AUC |  |  |  |  |  |  |  |  |  |  |  |
| iAUC glucose |  |  |  |  |  |  |  |  |  |  |  |
| iAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |
| iAUC insulin |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |
| iAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total AUC |  |  |  |  |  |  |  |  |  |  |  |
| tAUC glucose |  |  |  |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| 0-30 min |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Incremental AUC |  |  |  |  |  |  |  |  |  |  |  |
| iAUC glucose |  |  |  |  |  |  |  |  |  |  |  |
| iAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |
| iAUC insulin |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |
| iAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total AUC |  |  |  |  |  |  |  |  |  |  |  |
| tAUC glucose |  |  |  |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| 0-60 min |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Incremental AUC |  |  |  |  |  |  |  |  |  |  |  |
| iAUC glucose |  |  |  |  |  |  |  |  |  |  |  |
| iAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |
| iAUC insulin |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |
| iAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total AUC |  |  |  |  |  |  |  |  |  |  |  |
| tAUC glucose |  |  |  |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| 0-180 min |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Incremental AUC |  |  |  |  |  |  |  |  |  |  |  |
| iAUC glucose |  |  |  |  |  |  |  |  |  |  |  |
| iAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |
| iAUC insulin |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |
| iAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total AUC |  |  |  |  |  |  |  |  |  |  |  |
| tAUC glucose |  |  |  |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Data are means and standard deviations/median or interquartile ranges at baseline or follow-up or estimated within-group difference in change from baseline to follow-up with 95% confidence intervals. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, GLP-1: Glucagon-like-peptide 1, GIP: Gastric inhibitory polypeptide, tAUC: total area under the curve, iAUC: incremental area under the curve. | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 13 Other Pairwise comparisons of secondary outcomes derived from the mixed meal tolerance test | | | | | | | | | | | | | | | | | |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | HED vs. CON | P-value |  | MED vs. CON | P-value |  | DCON vs. CON | P-value |  | HED vs. DCON | P-value |  | MED vs. DCON | P-value |  | HED vs. MED | P-value |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Total AUC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-15 min |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-60 min |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC glucose |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-180 min |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC glucose |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC insulin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| tAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Incremental AUC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-15 min |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC glucose |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC insulin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-30 min |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC glucose |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC insulin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-60 min |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC glucose |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC insulin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GIPtotal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-180 min |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC glucose |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC C-peptide |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC insulin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1total |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC GLP-1active |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| iAUC paracetamol |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Data are estimated mean difference in changes between groups with 95% confidence intervals. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, GLP-1: Glucagon-like-peptide 1, GIP: Gastric inhibitory polypeptide, tAUC: total area under the curve, iAUC: incremental area under the curve | | | | | | | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 14 Within-group changes (0-16 weeks) cardiometabolic, body composition and fitness | | | | | | | | |
|  | CON | | DCON | | MED | | HED | |
|  | Change | 95% CI | Change | 95% CI | Change | 95% CI | Change | 95% CI |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Glycemic control |  |  |  |  |  |  |  |  |
| HbA1c (mmol/mol) |  |  |  |  |  |  |  |  |
| HbA1c (%) |  |  |  |  |  |  |  |  |
| Fasting glucose (mmol/l) |  |  |  |  |  |  |  |  |
| Fasting insulin (pmol/l) |  |  |  |  |  |  |  |  |
| Fasting C-peptide (pmol/l) |  |  |  |  |  |  |  |  |
| Glucose-lowering medication, No (%) |  |  |  |  |  |  |  |  |
| Reductiona |  |  |  |  |  |  |  |  |
| Discontinuationb |  |  |  |  |  |  |  |  |
| Intensificationc |  |  |  |  |  |  |  |  |
| Lipid-lowering medication, No (%) |  |  |  |  |  |  |  |  |
| Reductiona |  |  |  |  |  |  |  |  |
| Discontinuationb |  |  |  |  |  |  |  |  |
| Intensificationc |  |  |  |  |  |  |  |  |
| Blood pressure lowering medication, No (%) |  |  |  |  |  |  |  |  |
| Reductiona |  |  |  |  |  |  |  |  |
| Discontinuationb |  |  |  |  |  |  |  |  |
| Intensificationc |  |  |  |  |  |  |  |  |
| Lipids |  |  |  |  |  |  |  |  |
| LDL cholesterol (mmol/l) |  |  |  |  |  |  |  |  |
| Fasting triglycerides (mmol/l) |  |  |  |  |  |  |  |  |
| Blood pressure |  |  |  |  |  |  |  |  |
| Systolic (mmHg) |  |  |  |  |  |  |  |  |
| Diastolic (mmHg) |  |  |  |  |  |  |  |  |
| Fitness |  |  |  |  |  |  |  |  |
| Absolute VO2 max (ml/min) |  |  |  |  |  |  |  |  |
| Relative VO2 max (ml/kg/min) |  |  |  |  |  |  |  |  |
| Watt max (W/kg) |  |  |  |  |  |  |  |  |
| 1 RM chest press (kg) |  |  |  |  |  |  |  |  |
| 1 RM leg extension (kg) |  |  |  |  |  |  |  |  |
| Body composition |  |  |  |  |  |  |  |  |
| Body weight (kg) |  |  |  |  |  |  |  |  |
| BMI (kg/m2) |  |  |  |  |  |  |  |  |
| Data are least-squares means. CI: confidence intervals, CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise  aReduction defined as at least one step down on the pre-defined algorithm.  bDiscontinuation defined as, discontinuation of all drugs when therapeutic target was met.  cIntensification defined as at least one step up on the pre-defined algorithm. | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| eTable 15 Pairwise comparisons of the change in cardiometabolic, body composition and fitness | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | |
|  | HED vs. CON | P-value |  | MED vs. CON | P-value |  | DCON vs. CON | P-value |  | HED vs. DCON | P-value |  | MED vs. DCON | P-value |  | HED vs. MED | P-value |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Glycemic control |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| HbA1c (mmol/mol) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| HbA1c (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fasting glucose (mmol/l) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fasting insulin (pmol/l) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fasting C-peptide (pmol/l) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Glucose-lowering medication, No (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Reduction |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Discontinuation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Intensification |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lipid-lowering medication, No (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Reduction |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Discontinuation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Intensification |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Blood pressure lowering medication, No (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Reduction |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Discontinuation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Intensification |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lipids |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Total cholesterol (mmol/l) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LDL cholesterol (mmol/l) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fasting triglycerides (mmol/l)a |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Blood pressure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Systolic (mmHg) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Diastolic (mmHg) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fitness |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Absolute VO2 max (ml/min) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Relative VO2 max (ml/kg/min) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Watt max (W/kg) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 1 RM chest press (kg) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 1 RM leg extension (kg) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Body composition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Body weight (kg) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BMI (kg/m2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Data are estimated mean difference in changes between groups with 95% confidence intervals. CON: control group, DCON: Dietary control group, MED: Moderate volume exercise, HED: High volume exercise, HbA1c: Glycated hemoglobin 1Ac, GLP-1: Glucagon-like-peptide 1, GIP: Gastric inhibitory polypeptide | | | | | | | | | | | | | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| eTable 16 Adverse events after randomization | | | | | |
| Event | All n (%) | CON n (%) | DCON n (%) | MED n (%) | HED n (%) |
|  |  |  |  |  |  |
| Serious AE |  |  |  |  |  |
|  |  |  |  |  |  |
| All AE |  |  |  |  |  |
|  |  |  |  |  |  |
| Gastrointestinal |  |  |  |  |  |
| Nausea |  |  |  |  |  |
| Vomiting |  |  |  |  |  |
| Diarrhea |  |  |  |  |  |
| Constipation |  |  |  |  |  |
| Dyspepsia |  |  |  |  |  |
| Flatulens |  |  |  |  |  |
| Abdominal distension |  |  |  |  |  |
| Abdominal pain |  |  |  |  |  |
| Other |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| Infections |  |  |  |  |  |
|  |  |  |  |  |  |
| Musculoskeletal pain and discomfort |  |  |  |  |  |
| Back pain |  |  |  |  |  |
| Lower extremities |  |  |  |  |  |
| Upper extremities |  |  |  |  |  |
| other |  |  |  |  |  |
|  |  |  |  |  |  |
| Musculoskeletal injury, defined as pain or discomfort  resulting in inability to exercise for ≥7days |  |  |  |  |  |
| Back pain |  |  |  |  |  |
| Lower extremities |  |  |  |  |  |
| Upper extremities |  |  |  |  |  |
| other |  |  |  |  |  |
|  |  |  |  |  |  |
| Complications associated with clinical or experimental procedures |  |  |  |  |  |
|  |  |  |  |  |  |
| Metabolism and nutrition disorders |  |  |  |  |  |
| Decreased appetite |  |  |  |  |  |
| Increased appetite |  |  |  |  |  |
| Hunger |  |  |  |  |  |
| Other |  |  |  |  |  |
| Nervous system disorders |  |  |  |  |  |
| Headache |  |  |  |  |  |
| Dizziness |  |  |  |  |  |
| Other |  |  |  |  |  |
|  |  |  |  |  |  |
| Events related to dysglycemia |  |  |  |  |  |
| Events related to blood pressure management |  |  |  |  |  |
|  |  |  |  |  |  |
| Other |  |  |  |  |  |
|  |  |  |  |  |  |
| Values are number and percentage (%) of participants with adverse event for each group. All events are self‐reported to reported to the study nurse, dietitian or trainers and occurred after randomization. | | | | | |